[4] The company subsequently relocated its headquarters to Mountain View, California, and its initial public offering of 9 million shares took place on the NASDAQ stock exchange in March 2000.
This suit represented one of several legal battles between the two companies, each of which accused the other of infringing on their patents.
[6] On October 26, 2000, a jury in California found Aclara guilty of misappropriating trade secrets and awarded Caliper $52,568,000.
Its best-known product was its proprietary eTag (short for "electrophoretic tag") assay technology designed for use on proteins and nucleic acids.
[10][11] In October 2004, Aclara entered into an arrangement with GlaxoSmithKline to test these assays for potential use in cancer drug development.